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Summary. The 29th Annual North American Cystic Fibrosis Conference was held in Phoenix,
Arizona on October 8–10, 2015. Abstracts were published in a supplement to Pediatric
Pulmonology.1 In this review, we summarize presentations in several of the topic areas addressed
at the conference. Our goal is to provide an overview of presentations with relevance to emerging
or changing concepts in several areas rather than a comprehensive review. Citations from the
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The ubiquitin-activating enzyme inhibitor PYR-41 was
shown to enhance the corrector activity of VX-809
(Goeckeler-Fried et al., 10), and new inhibitors of
ubiquitin E3 ligases appear to rescue F508del CFTR
(Chung et al., 13). Different approaches for other types of
mutations were also discussed, such as readthrough
agents for premature termination codons. These drugs
permit generation of full length protein, but tend to insert
certain amino acids (tryptophan, cysteine, or arginine)
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PATHOPHYSIOLOGY OF CYSTIC FIBROSIS (CF) 
LUNG DISEASE
The theme of personalized or precision medicine was 
prevalent throughout the basic science sessions. This is 
exemplified by the emphasis on “theratyping,” grouping 
cystic fibrosis transmembrane conductance regulator 
(CFTR) gene mutations by their mechanistic response 
to different therapeutics.2 The response of missense and 
in-frame deletion mutants to CFTR correctors and 
potentiators was discussed (Harness-Brumley et al., 
S17.1), with further data provided in workshop sessions 
(Cai et al., 3; Sorscher et al., 199). A common theme was 
that responses to CFTR modulators are mutation specific, 
with differential responses among various CFTR alleles 
not always related to functional class. For example, the 
VX-809 corrector designed to address CFTR misprocess-
ing was more effective with the R117H mutation (a 
conductance mutation) than N1303K (a misprocessing 
mutation), whereas the gating mutations S1251N and 
G551D had differential responses to the potentiator VX-
770 (Cholon et al., 6). Thus, the historic division of CFTR 
mutations into different functional classes is not 
necessarily predictive of responses to specific CFTR 
modulator therapies, with implications for development 
and use of these drugs.
Novel approaches toward improving CFTR protein 
function were also explored. Many CFTR mutations, 
including F508del, experience excessive protein degra-
dation via the ubiquitin-dependent degradation pathway.
effectively creating missense mutations. Activity of
CFTR proteins generated by readthrough therapies
depends upon the location of the premature stop codon
(Pranke et al., 12 and 153), and activity of some corrected
proteins can be increased by CFTR potentiators (Mutyam
et al., 219). These findings suggest that combination of a
readthrough agent plus a CFTR potentiator may be
needed for clinical efficacy.3 These basic science studies
form the underpinning for future, novel clinical therapeu-
tic approaches in CF.
All of these studies demonstrate the need for a precision
medicine approach to determine the optimal drugs and
drug combinations for specific CFTR mutations. Several
groups are examining the potential of organoids to test
individual patients’ responses to various drugs. Organoids
are hollow spheres of epithelial cells formed from cells
obtained from intestinal or airway tissue biopsies. CFTR
activity can be assessed by whether the spheres grow or
shrink in response to drugs that alter CFTR function
(Amaral, S9.2). Several groups highlighted the potential
utility of this approach (Ramalho et al., 18; Berkers et al.,
210; Kwok et al., 61; Sorio et al., 163; Boecking et al.,
188; Caldrer et al., 259). While the use of organoids
represents an exciting approach to precision medicine in
CF, all of the investigators noted the need for further work
to ensure that the ex vivo responses in organoids are
predictive of clinical benefit.
Testing of new therapies requires robust animal models,
but these efforts are hindered by the fact that the CF
knockout mouse model does not develop significant
pulmonary disease. The development of the F508del CF
rat model (Lambert et al., 85) represents a significant
advance, in part, because the use of CRISPR technology to
engineer a specific CFTR mutation potentially paves the
way for mutation specific animal models. Importantly, the
CF rat appears to exhibit a pulmonary phenotype with
mucus accumulation and difficulty clearing intratracheally
administered Pseudomonas (Birket et al., 139), potentially
providing a much needed small animal model of CF lung
disease.
Insights were also derived from other animal models. A
relationship between lowered airway surface liquid
(ASL) pH and increased mucus viscosity with greater
impact in smaller airways was shown in the CF pig (Tang
et al., 91; Li et al., 92). Pharmacological correction of
reduced ASL pH improved bacterial killing and ASL
viscosity, potentially identifying a new therapeutic
strategy (Shah et al., 97). The glandular mucus transport
defects in the airways of the “European” CF pig, which
are consistent with findings in intestinal mucosa of the CF
mouse, were reviewed in a symposium session (Hansson
et al., S2.2). These findings highlight the potential benefit
of improving mucus properties with hydrating agents,
reducing agents, or improved CFTR function (Button,
S2.1; Rowe et al., S2.4). The CF ferret led to new insights
in non-pulmonary phenotypes including bone develop-
ment (Havasi et al., 593), glucose intolerance (Yi et al.,
595), and macrophage function (Keiser et al., 88). The
multitude of available CF animal models including
mouse, rat, ferret, and pig represents a boon for CF
researchers, particularly since some of these models
appear to develop lung disease. However, variations in
phenotype highlight the limitations of animal models and
the need to verify the relevance of pathophysiological
mechanisms in humans.
Challenges remain in understanding the role of the
microbiome and interbacterial interactions in CF lung
disease. Regional differences of the microbiome in vivo
were assessed in nine patients undergoing bronchoal-
veolar lavage (BAL) from three regions of the right
lung jointly with protected brush sampling. The
predominant taxa observed were similar between
regions despite higher inflammation in the more
diseased regions, as determined by concomitant CT,
possible due to host-factors responsible for lung damage
(Hogan et al., 307).
A rigorous longitudinal study addressed changes in
microbiome related to exacerbations using culture-
enriched metagenomics sequencing. Six patients contrib-
uted three sputum samples per week for a year. Diversity
changed after exacerbations in some but not all patients
without a consistent pattern or specific bacterial taxa
contributing to changes (Whelan et al., 302 and 303). In
contrast, a multi-center German study in 10 children using
oral swab and sputum found that the presence of oral flora
was associated with clinical stability. No consistent
microbiome alterations occurred during exacerbations
(Boutin et al., 323).
Metabolic activity of the microbiome remains chal-
lenging. Distinction of CF from non-CF sputum samples
was more evident by host-derived sphingolipids than by
Pseudomonas aeruginosametabolites (Quinn et al., 308).
Sputum from patients with stable lung function were
found to have a more conservative metabolome,
especially fewer antibiotic-resistance genes than those
with declining lung function (Bacci et al., 306).
Nontuberculousmycobacteria (NTM) are ubiquitous in
soil and water, yet airborne transmission can occur
(Malcolm et al., 296). Detection of NTM remains
challenging by culture and molecular methods. Various
culture media for rapidly growing mycobacteria were
compared (Preece et al., 376). The investigators con-
cluded that their novel medium, “details to be published,”
had a 96–98% detection rate compared to currently used
methods ranging from 83% and 98% for different cepacia
agars. In addition, the mycolic lipid acid barrier hinders
lysis of mycobacteria for molecular detection. Even with
an enhanced bacterial lysis protocol, the detection rate of
NTM in spiked samples by sequencing was only 31%
(Caverly et al., 372).
approval was examined using CF Foundation Patient
Registry (CFFPR) data (Bai et al., 246). Using data from
all patients on ivacaftor (n¼ 999) plus age and gender-
matched controls (n¼ 4932), the researchers found a
decreased relative risk of death (RR 0.37, 95%CI
0.15–0.93) and lung transplantation (RR 0.19, 95%CI
0.05–0.66) in those on ivacaftor compared to controls.
Hospitalization rates for all causes and pulmonary
exacerbations were also lower in those on ivacaftor. In
a separate study of patients with severe lung disease
(FEV1< 40%predicted) followed for amedian of 3 years,
treatment with ivacaftor (n¼ 21) was associated with a
reduced rate of death or lung transplantation (HR 0.13, CI
0.04–0.43) compared to controls (n¼ 35) (Barry et al.,
226). These studies confirm the substantial clinical impact
of ivacaftor suggested by earlier clinical trials.
Several smaller studies also examined clinical out-
comes after ivacaftor treatment. A single center study of
patients in Irelandwith the G551Dmutation (Ronan et al.,
205 and 206) showed improvements in FEV1 (þ10.3%),
BMI (þ1.2 kg/m2), sweat chloride (–58mmol/L), and
decreased rate of pulmonary exacerbations after initiation
of ivacaftor in 33 patients. Improvements in chest CT
score and decreased systemic inflammation (IL-6 and
C-reactive protein) were also found. In a sub-group of 18
adults, treatment with ivacaftor did not result in changes
in fecal elastase or gut inflammation; however, gut
microbiota shifted with an increase in taxa typically
associated with improved health. In a study from Toronto,
changes in spirometry and lung clearance index (LCI)
measured using multiple breath washout were compared
in 10 patients with gating mutations before and after
ivacaftor (Kane et al., 232). Over a median 37 days, LCI
improved significantly with a decrease of 2.3 (3.1 to
1.4), while FEV1 increased 12%. There was no
significant correlation between FEV1 and LCI changes.
KONDUCT, a randomized, placebo-controlled clinical
trial which led to ivacaftor approval for people with
R117H, included 69 patients ages 6 years treated for
24 weeks.6 Patients treated with ivacaftor had decreased
sweat chloride and improved CFQ-R respiratory domain
scores; lung function was improved in adults, but not in
children. The G551D Observational Expanded and
Extended Study (GOAL-E2) is a post-approval longitu-
dinal study of patients before and after initiation of
ivacaftor. Data from a subgroup analysis of CF patients
ages6 years with R117Hwho started (n¼ 60) or did not
start (n¼ 20) ivacaftor were presented (Sagel et al., 190).
Patients who started ivacaftor were generally older,
although 22/60 patients were under 18 years. Improve-
ments in FEV1% predicted and CFQ-R and decreases in
sweat chloride over 6months were similar to those seen in
the clinical trial, regardless of age or poly-T tract status.
Data from early clinical trials of N91115, an oral
S-nitrosoglutathione reductase (GSNOR) inhibitor with
CLINICAL TRIALS
The NACFC 2015 program highlighted ground-
breaking results from clinical trials aimed at treating 
CFTR protein dysfunction. Data from post-approval 
studies of ivacaftor (VX-770) for people with the 
G551D and other gating mutations and the R117H 
mutation continue to add to our understanding of CFTR 
pathophysiology and restoration. Advances in microbiol-
ogy, anti-inflammatories, and airway surface liquid 
restoration were also notable.
CFTR Modulators
The combination therapy lumacaftor (VX-809)/ iva-
caftor (Orkambi1) was approved by the FDA in July 2015 
for use in patients with CF ages 12 years of age and older 
with two copies of the F508del mutation. Two large phase 
III clinical trials (n ¼ 1108 subjects), TRAFFIC and 
TRANSPORT, demonstrated clinical benefit for patients 
on lumacaftor/ivacaftor with improvement in lung 
function (mean FEV1% predicted improvement 2.6–
4.0%) and reduction in pulmonary exacerbations of 
30–39% compared to the placebo group.4 Patients 
completing TRAFFIC and TRANSPORT were eligible 
for roll-over into PROGRESS, a 96-week, open-label 
study of lumacaftor/ivacaftor; interim data from week 24 
(48 weeks from initial study enrollment) were presented 
(Konstan et al., 211). Reassuringly, patients enrolled in 
PROGRESS maintained improvements in lung function 
seen in TRAFFIC and TRANSPORT. Improvements in 
body-mass index (BMI), Cystic Fibrosis Questionnaire-
Revised (CFQ-R) respiratory domain health-related 
quality-of-life score, and rates of pulmonary exacerbation 
similar to those seen in the original trials were also 
maintained. Patients initially in the placebo group had 
similar and sustained FEV1 improvements with luma-
caftor/ivacaftor treatment. There were no new safety 
concerns identified.
A phase III open-label study of ivacaftor in children 
ages 2–5 years with a gating mutation, the KIWI study, 
resulted in approval of ivacaftor for this age group.5 A
1-year follow-up study, KLIMB, demonstrated sustained 
improvements in fecal elastase and immunoreactive 
trypsinogen similar to those seen in KIWI over 72 weeks 
(Rosenfeld et al., 247). Notably, 8/33 patients had 
elevations in liver enzymes >8 times the upper limit of 
normal. Six of the eight patients were able to restart 
therapy after a drug interruption, with two permanently 
discontinuing drug due to liver function abnormalities, 
confirming the importance of careful monitoring of liver 
enzymes in young children treated with ivacaftor.
Real-world experience with ivacaftor for patients with 
G551D and other gating mutations was presented by 
several groups. The impact of ivacaftor on mortality and 
lung transplantation in the 2 years following FDA
potential CFTR-modulatory and anti-inflammatory
effects, were presented. A phase 1 pharmacokinetic
open-label study of N91115 given over 14 days to CF
subjects showed that the drug was safe and well-tolerated
with overall exposure similar to previous findings in
healthy subjects (Taylor-Cousar et al., 250). A phase Ib
double-blind, randomized, placebo-controlled trial
comparing three doses of N91115 in adults with CF
homozygous for F508del (n¼ 48) found no safety
concerns over 1 month and a modest decrease in sweat
chloride in the highest dose group (Donaldson, 270). A
phase II study in adults with CF began enrollment in
November 2015 (clinicaltrial.gov NCT02589236). This
trial is unique in that N91115 is being studied in
combination with lumacaftor/ivacaftor with the expecta-
tion that improved CFTR trafficking and stability due to
increased S-nitrosoglutathione will further augment the
impact of lumacaftor/ivacaftor on CFTR function.7
Gene Therapy
Results from a Phase IIb double-blind, placebo-
controlled trial of nebulized CFTR gene-liposome
complex were presented and subsequently published
(Alton et al., 192).8 The study, part of the UK CF Gene
Therapy Consortium translational program, enrolled
140 CF patients ages 12 years and older from 18 sites
and randomized patients to monthly nebulization with
the gene-liposome complex or 0.9% saline for 12 months
(clinicaltrials.gov NCT01621867). There was a statisti-
cally significant difference in the primary outcome,
FEV1% predicted at 12 months of 3.7% (95%CI 0.1–7.3,
P¼ 0.046), largely due to a more rapid decline in FEV1 in
the placebo group (4.0%, CI6.6 to1.4) compared to
relative stability in the treatment group (0.4%, CI 2.8
to 2.1). The study found nomajor safety concerns. Overall
the benefits were modest, and the investigators suggested
that further improvements with more potent and efficient
gene vectors for delivery are needed before gene therapy
may be suitable for clinical care.
Microbiology
Results from three clinical trials focused on treatment
of methicillin-resistant Staphylococcus aureus (MRSA)
were presented. The STAR-too trial, enrolling patients
with new onset MRSA infection, compared use of a
rigorous combination therapy to observation alone,
that is, standard of care. The primary endpoint of
MRSA-culture negativity at day 28 was met by 82% in
the treatment group compared to 26% in the observation
arm (Goss, S11.3). Typing of the MRSA isolates from the
trial showed a shift from the SCCmec II in prior studies to
predominance of SCCmec IV type (USA300). Nasal
colonization occurred in 32% of participants but skin
colonization was rare (Muhlebach et al., 360). The
recently completed 20-center double-blind, placebo-
controlled, Phase II study of vancomycin hydrochloride
inhalation powder (AeroVancTM) enrolled 87 patients
with chronic MRSA and met the primary endpoint of
reduced MRSA colony forming units in sputum at
day 29 (Dasenbrook, S11.4). Bronchoconstriction was
observed at a higher rate in the AeroVancTM group and
appeared dose-dependent. The two-center Persistent
MRSAEradication Protocol (PEMP)-blinded, pla-
cebo-controlled trial used the intravenous formulation
of vancomycin for inhalation (Dezube et al., 327) in
combination with oral TMP-SMX and rifampin. Among
the 16 subjects who initiated study drug, three patients
were withdrawn for bronchospasm. Rifampin resistance
developed in five subjects. A report from France (Rubira
et al., 330) described 15 patients with glycopeptide-
intermediate-resistant MRSA (GISA) with a high rate of
persistence. Treatment protocols used either prior, or after
appearance of GISAwere too variable to allow evaluation
of GISA risk factors and outcomes. Jointly such reports
indicate that antibiotics should be used cautiously for
MRSA.
Liposomal amikacin for inhalation (LAI) is a novel
formulation of amikacin developed for people with CF
and chronic P. aeruginosa or nontuberculous mycobacte-
rial infections.9 An initial clinical trial, CLEAR-108,
enrolled patients with CF age 6 years with chronic
P. aeruginosa infection. Participants were randomized to
receive 3-monthly cycles of either LAI once daily or
tobramycin inhalation solution (TIS) twice daily. Initial
data showed non-inferiority of LAI compared to TIS
(Bilton et al., NACFC 2013, Abstract 23510). Eligible
patients were able to roll-over to an open-label study of
LAI, CLEAR-110, for 12 additional cycles over 2 years
(Konstan et al., 212). Of the 206 patients enrolled, 134
completed 12 cycles of LAI; 44 prematurely discontinued
the drug. After 12 cycles of LAI, participants hadminimal
change in P. aeruginosa density compared to baseline,
pretreatment levels. Absolute FEV1 increased3.5% but
FEV1% predicted declined 3%. Side effects were
primarily respiratory and unrelated to study drug.
Anti-Inflammatory Treatment
CTX-4430 is a small molecule inhibitor of leukotriene
A4 hydrolase that acts by reducing the inflammatory
mediator leukotriene B4. A phase I safety study of
ascending doses was performed in 17 CF patients over
2 weeks (Ahuja et al., 287). The drug appeared safe and
well-tolerated with no deleterious effects on lung
function, and no changes in circulating neutrophils or
airway bacterial load. There were trends noted in
reduction of sputum neutrophils, elastase, and blood
CRP, including a 65% reduction in sputum neutrophils in
the highest dose group. A phase II trial is currently
recruiting adults 18 years and older with lung function
50% (clinicaltrials.gov NCT 02443688).
therapy for P. aeruginosa.13,14 The approach to patients
who fail to eradicate is still unresolved (Ratjen, S3.2).
Persistence of P. aeruginosa could be secondary to host or
bacterial factors. Using P. aeruginosa isolates obtained
during the Early Pseudomonas Infection Control (EPIC)
trial, isolates that persisted show higher rates of genetic
mutations during the first year of infection compared to
chronic infection (Jorth et al., 300).
Eradication strategies are associated with decreasing
incidence of chronic P. aeruginosa as demonstrated using
data from the CFFPR (Crull et al., 385). In patients 13
years, the incidence of chronic P. aeruginosa, defined as
50% of cultures being positive, decreased from 14.3%
in 2003 to 6.4% in 2012. In this epidemiologic study,
treatment details were not reported. A prospective study
of children born after 2002 and followed for a median of
5.1 years (n¼ 6,277) addressed the current incidence of
P. aeruginosa and the transition to chronic and mucoid
infection (Khan et al., 294). Fifty-eight percent acquired
P. aeruginosa at a median age of 1.1 years, and 94% of
initial isolates were non-mucoid. Of the 27% of subjects
progressing to chronic infection, mucoid P. aeruginosa
was present in 18% at a mean (SD) 1.8 (2.2) years after
initial infection. Initial mucoid infection was associated
with higher risk of persistent infection.
Novel epidemiological and in vitro data address the
choice of antibiotics for P. aeruginosa treatment. A multi-
center study extended prior observations of potential
interference of azithromycin with inhaled tobramycin
(Happoldt et al., 292).15 Using data from a clinical trial
comparing efficacy of TIS to inhaled aztreonam, patients
on combination TIS-azithromycin had no improvement in
lung function and a decrease in quality-of-life question-
naires compared to those on inhaled aztreonam or those on
single therapy TIS. In vitro studies using clinical
P. aeruginosa isolates grown in a biofilm model
demonstrated reduced bacterial killing and induction of
aminoglycoside efflux pumps by azithromycin as potential
mechanisms. A prospective clinical trial examining the
effect of combining azithromycin with inhaled tobramycin
for patients with CF and chronic P. aeruginosa is planned
(clinicaltrials.gov NCT02677701). The effect of inhaled
antibiotics on bacterial killing was also studied using
clinical isolates from patients on (i) alternating months
TIS; (ii) alternating months inhaled aztreonam; or (iii)
alternatingTIS and aztreonam (Shih et al., 366). In general,
aztreonam failed to reduce biofilms, whereas TIS appeared
more effective. Subjects on alternating antibiotics had the
lowest resistance.
Psychosocial Issues
Elevated rates of anxiety and depression among
adolescents and adults with CF and their parental
caregivers may affect adherence, health outcomes, health
Restoration of the Airway Surface Liquid Layer
P-1037 is an ENaC inhibitor thought to aid in mucus 
hydration and mucus clearance in CF. In a Phase I safety 
study, healthy subjects (n ¼ 73) were enrolled in a 
randomized, double-blind, placebo-controlled study of 
dose escalation of P-1037 and placebo (nebulized saline); a 
CF cohort (n ¼ 8, 2 on placebo) was also evaluated (Donn 
et al., 217). Potassium levels and urine concentrations were 
monitored due to the potential impact of ENaC inhibitors 
on renal electrolyte transport and resultant hyperkalemia.11 
At the highest dose studied, there were no changes in 
plasma K levels and drug excreted in the urine was very 
low; no adverse respiratory effects were noted. A phase II 
trial is now planned for P-1037 (renamed VX–371) in 
combination with hypertonic saline.
CLINICAL MANAGEMENT ISSUES
Imaging
Advances in established chest CT methods for detecting 
structural lung disease using the PRAGMA scoring system 
as a more sensitive approach were reviewed in the 
“Assessing Presymptomatic Children” symposium (Rose-
now, S10.2).12 PRAGMA-CF chest CT scores for gas 
trapping were not associated with air trapping on lung 
function or multiple breath washout, suggesting non-
ventilatory defects (Rosenow et al., 216). While methodo-
logical improvements have reduced the radiation dose 
from chest CT, non-radiation-based imaging methods, 
such as MRI, have also seen increasing use in CF. In 57 
children with CF, MRI scores differentiated those with 
chronic P. aeruginosa infection from those without; MRI 
scores also decreased after intravenous antibiotic treatment 
of a CF pulmonary exacerbation (Stahl et al., 209). Newer 
MRI-based technologies are also finding utility in CF. 
Ultra-short echo time (UTE) MRI revealed lung structural 
abnormalities that correlated with those observed on CT, as 
well as with ventilation defects seen on hyperpolarized gas 
MRI in five adolescents with CF (Thomen et al., 403). 
Similar findings were reported by a second group (Roach 
et al., 417). While promising, these newer MRI technolo-
gies will require substantial further development before 
they are ready to be used as research or clinical outcome 
measures.
Infection
Numerous investigators demonstrated progress in 
management of P. aeruginosa, S. aureus, and other 
pathogens.
Current recommendations by European and the US 
guidelines are use of inhaled tobramycin as first line of
care utilization and cost.16–18 The importance of mental
health was highlighted in a plenary session entitled,
“There is No Health Without Mental Health,” (Quittner,
Elborn and Smith, P3) which offered a comprehensive
review of mental health issues in CF and introduced
guidelines established by the Cystic Fibrosis Foundation
and the European Cystic Fibrosis Society.19 These
guidelines call for annual screening of adolescents and
adults for depression and anxiety, with appropriate
interventions and reassessment.
Adherence to CF therapies impacts outcomes, and the
relationship between disease severity, treatment com-
plexity, and psychosocial concerns are important areas of
study in CF. Factors linking socioeconomic status and
respiratory outcomes in children and the need for
appropriate resources to support adherence were explored
(Oates et al., 661).20 Strategies to improve adherence to
CF therapies include promotion of healthy lifestyles
(Wilcox et al., 623), use of home spirometry and symptom
diaries (Lechtzin et al., 628), inpatient medication self-
administration (Khan et al., 624), and attention to spiritual
needs (Grossoehme et al., 637).
Adolescents and young adults must assume increasing
responsibility for their own health care as they prepare to
transition from pediatric to adult CF care. Extensive
efforts are underway to improve the transition process,
including structured and mentored quality improvement
(QI) programs (Baker et al., 640).21 Quality improvement
initiatives from individual centers involve use of transi-
tion checklists, combined pediatric and adult team
meetings, provider handoffs, and transition-specific
educational materials (Burns et al., 610; McLauchlan
et al., 611; Ruddy et al., 612; Becker et al., 613; Cumming
et al., 614; Baum et al., 615).
Transition-related process of care was examined using
the CFFPR (Sawicki et al., 486). Transfers of care from
pediatric to adult providers most commonly occurred at
age 20 with median of 99 days between last pediatric and
first adult outpatient encounter. Patients with markers of
better overall health during the last year of pediatric care
had longer gaps in care. Minimal disruption in care
occurred during transfer of individual patients from
pediatric to adult CF care. In a separate study, a majority
of adolescents and young adults indicated they would use
social media for CF education, peer support, and
communicating with health care providers (Anand
et al., 663). Infection control restrictions support the
need to enhance social media platforms.
Palliative care focuses on enhancing quality of life for
people with serious illness. Funded research and center-
based QI initiatives are yielding new information about
advance care planning (ACP), end-of-life care, provider
education, and other aspects of palliative care in CF. Chen
et al.22 reported that most adults with CF, regardless of
disease severity, are open to conversations with health
care providers about goals of care and end-of-life care
issues. Adolescents with advanced disease and their
pediatric CF providers were also found to be receptive to
ACP (Kazmerski et al., 666). Using data from the US
adult CF care programs, Dellon et al.23 reported more
ACP occurs now than in previous reports, but often late in
the disease. There appears to be a wide variation in ACP
practices among care centers.
Providing quality palliative care to patients with CF
necessitates appropriate support and education for health
care providers around palliative and end-of-life care
issues. Goggin and Cohen found that even experienced
CF care providers reported lacking preparation and
knowledge in end of life care and desired more
education.24 Linnemann et al.25 created and implemented
a palliative care curriculum for CF care providers
addressing supportive care resources, pain and symptom
management, communication and psychosocial skills that
improved self-assessed comfort level with core palliative
care skills. Other centers reported observations from
integrating specialty palliative care into the care of people
with CF and suggested that, even with availability of
expert consultation, palliative, and end-of-life care needs
and practices specific to CF warrant further investigation
(Liberman et al., 646; Rabinowitz et al., 647).
Quality Improvement
Quality improvement is defined as an implementation
of system changes that drive care processes and result in
measurable improvement. In this section, we highlight
some of the important clinical QI work presented at the
2015 NACFC meeting with a focus on interventions
aimed to achieve systems of best practice, patient and
family engagement, and use of registry data to identify
areas for improvement. Lastly, we discuss future
strategies for successful QI implementation.
Centers reported interventions that increased in-clinic
services to improve patient convenience and guideline
adherence (Ghazala et al., 524; Joshi et al., 534). At
Nemours Children’s Specialty Care, bundled intervention
with in-clinic access to fasting glucose, pre-clinic
identification of eligible patients, andCFnurse coordinator
reminders led to an increase in screening for CF related
diabetes from36% to 86%of eligible patients (Smith et al.,
543). Other centers used phone calls, reminder letters, and
education of staff to better adhere to guidelines (McDo-
nagh et al., 516; Collins et al., 523). A recent quality report
described improved patient adherence to quarterly visits,
cultures, and biannual lung function through a nursing-led
appointment tracking system.26 Reporting important
contextual information, such as the size of center, patient
demographics, and team composition allows other centers
to ascertainwhether certain elements of these interventions
may be applicable to their clinics.
et al., 530). Infants who received the intervention had
significant improvements in weight-for-height z-score by
24 months of age (0.6 to 1.0, P< 0.001).
As new guidelines emerge and the pipeline of
therapeutics matures, systems of care must be developed
in parallel to facilitate the opportunity for all patients to
achieve best clinical outcomes. System measurements,
such as through the CFFPR or an electronic medical
record, allow for dynamic feedback to improve care.
Active family partnership and/or patient-level factors
assessed through site-specific and experience surveys will
enrich and direct personalized care. Similarly, compara-
tive effectiveness trials can be used to evaluate both
efficacy and patient experience.30 Publication of QI work
should adhere to the standards of reporting guidelines to
learn from the successes and challenges among care
centers.31,32 Lastly, committed care teams must take up
the challenge of developing and testing high quality care
systems despite competing responsibilities. Support of
clinical personnel should be a priority to aid in the
acceleration of CF quality care (Walker et al., 529).
CONCLUSIONS
The 2015 North American Cystic Fibrosis Conference
presented updates on many exciting new concepts and
advances. Progress continues to bemade in understanding
the basic pathophysiology of CFTR, mucus, and
infections in the CF lung, with implications for new
treatment strategies. There has been impressive progress
in clinical trials of new therapies that are likely to
transform CF care in the near future. Clinical manage-
ment of CF is evolving rapidly through application of
QI methods, and increased attention to individualized
patient goals and psychosocial factors.
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